NCT02077465View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 11, 2014

Primary Completion Date

October 27, 2014

Study Completion Date

October 27, 2014

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Andecaliximab

400 mg andecaliximab administered intravenously

DRUG

Placebo to match Andecaliximab

Placebo to match andecaliximab administered intravenously

Trial Locations (5)

14203

University at Buffalo CTRC, Buffalo

32806

Compass Research, LLC, Orlando

33136

Advanced Pharma CR, LLC, Miami

33169

Elite Research Institute, Miami

37920

Volunteer Research Group, Knoxville

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY